17.09.2015 13:10:54
|
Akorn Announces Launch Of Promethazine Syrup Formulations - Quick Facts
(RTTNews) - Akorn, Inc. (AKRX, AKRN.OB) announced it has launched Promethazine Hydrochloride and Phenylephrine Hydrochloride Syrup (Promethazine/Phenylephrine) and Promethazine Hydrochloride, Phenylephrine Hydrochloride and Codeine Phosphate Syrup CV. The company said the launches follow approval of abbreviated new drug applications for both products from the U.S. FDA in December 2014.
Promethazine/Phenylephrine Syrup is indicated for the temporary relief of upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. The fruit-flavored Promethazine/Phenylephrine Syrup is marketed under Akorn's Hi-Tech Pharmacal label.
Promethazine/Phenylephrine/Codeine Syrup is indicated for the temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy and the common cold.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Akorn Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |